TX HHS Form 1329. Kidney Health Care Program Drug Rebate Agreement

The TX HHS Form 1329, Kidney Health Care Program Drug Rebate Agreement, is a crucial document that helps solve the problem of managing drug rebates between manufacturers and healthcare providers. This form is typically used in situations where pharmaceutical companies need to provide rebates for drugs purchased by or on behalf of clients participating in the Kidney Health Care Program (KHC). The agreement outlines the responsibilities of both parties, including the manufacturer's obligations to report pricing data and make rebate payments.

The key features of this form include the definition of terms such as Average Manufacturer Price (AMP), Best Price, and Covered Outpatient Drugs. The agreement also specifies the requirements for reporting pricing data and making rebate payments, including the calculation of the Rebate Payment amount based on Program Utilization Data. Additionally, the form outlines the manufacturer's responsibilities to comply with applicable state and federal laws and regulations.

In summary, the TX HHS Form 1329 is a vital document that facilitates the process of drug rebates between manufacturers and healthcare providers participating in the KHC program. By understanding the terms and conditions outlined in this agreement, parties can ensure compliance with relevant laws and regulations, while also promoting transparency and accountability in the reimbursement process.

• The form is used to manage drug rebates between manufacturers and healthcare providers participating in the Kidney Health Care Program (KHC).
• The agreement outlines the responsibilities of both parties, including reporting pricing data and making rebate payments.
• The Rebate Payment amount is calculated based on Program Utilization Data.